SV2003001115A - Compuestos de espiropiperidina como ligandos para el receptor orl-1, ref. pc9989. - Google Patents
Compuestos de espiropiperidina como ligandos para el receptor orl-1, ref. pc9989.Info
- Publication number
- SV2003001115A SV2003001115A SV2002001115A SV2002001115A SV2003001115A SV 2003001115 A SV2003001115 A SV 2003001115A SV 2002001115 A SV2002001115 A SV 2002001115A SV 2002001115 A SV2002001115 A SV 2002001115A SV 2003001115 A SV2003001115 A SV 2003001115A
- Authority
- SV
- El Salvador
- Prior art keywords
- orl
- spyropiperidine
- ref
- receptor
- links
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
UN COMPUESTO DE FORMULA: (VER FORMULA)O UNA SAL, PROFARMACO O SOLVATO DEL MISMO, EN LA QUE TODOS LOS GRUPOS R1 Y R2 SON HIDROGENO; A ES UN AZAHETEROANILLO BENZOCONDENSADO; W1-W2 ES CH2-CH2; X1-X2 ES CH2-CH2; Y Z ES METILENO O CARBONILO; O SIMILARES, ES UN LIGANDO PARA EL RECEPTOR ORL-1 Y ES UTIL PARA TRATAR O PREVENIR EL DOLOR, UN TRASTORNO DEL SNC O SIMILARES EN MAMIFEROS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30107901P | 2001-06-26 | 2001-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2003001115A true SV2003001115A (es) | 2003-03-18 |
Family
ID=23161844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2002001115A SV2003001115A (es) | 2001-06-26 | 2002-06-25 | Compuestos de espiropiperidina como ligandos para el receptor orl-1, ref. pc9989. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20030078278A1 (es) |
EP (1) | EP1399432A1 (es) |
JP (1) | JP2005521630A (es) |
AP (1) | AP2002002562A0 (es) |
BR (1) | BR0211305A (es) |
CA (1) | CA2450550A1 (es) |
MX (1) | MXPA03011956A (es) |
PA (1) | PA8549101A1 (es) |
PE (1) | PE20030132A1 (es) |
SV (1) | SV2003001115A (es) |
UY (1) | UY27355A1 (es) |
WO (1) | WO2003000677A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003064425A1 (en) * | 2002-01-28 | 2003-08-07 | Pfizer Japan Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
PT1491212E (pt) | 2002-03-29 | 2012-11-16 | Mitsubishi Tanabe Pharma Corp | Medicamento para distúrbios de sono |
MXPA05002622A (es) * | 2002-09-09 | 2005-09-08 | Johnson & Johnson | Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano. |
WO2004041279A1 (en) * | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Gamma-aminoamide modulators of chemokine receptor activity |
WO2004089307A2 (en) | 2003-04-04 | 2004-10-21 | Merck & Co. Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
US7354925B2 (en) | 2004-03-29 | 2008-04-08 | Pfizer Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists |
WO2005117862A1 (en) * | 2004-06-03 | 2005-12-15 | Pfizer Limited, | Treatment of urinary conditions including incontinence |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY158766A (en) | 2005-04-11 | 2016-11-15 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
EP1890696A4 (en) * | 2005-06-02 | 2010-05-05 | Janssen Pharmaceutica Nv | Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives |
CA2612299A1 (en) * | 2005-06-17 | 2006-12-21 | Pfizer Inc. | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
JP2008543826A (ja) * | 2005-06-17 | 2008-12-04 | ファイザー株式会社 | ORL1−受容体アンタゴニストとしてのα−(アリール−またはヘテロアリール−メチル)−β−ピペリジノプロパン酸化合物 |
EP1940401B1 (en) | 2005-10-18 | 2012-07-11 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
AU2006306497A1 (en) * | 2005-10-24 | 2007-05-03 | Janssen Pharmaceutica, N.V. | 3-piperidin-4-yl-indole ORL-1 receptor modulators |
WO2007057775A1 (en) * | 2005-11-21 | 2007-05-24 | Pfizer Limited | Spiropiperidine derivatives |
GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
CL2007002950A1 (es) | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer |
WO2008056687A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Nouveau dérivé de spiropipéridine |
MX2009005641A (es) * | 2006-11-28 | 2009-06-05 | Janssen Pharmaceutica Nv | Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona. |
CA2683598C (en) * | 2007-04-09 | 2015-11-17 | Janssen Pharmaceutica Nv | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
HUE039416T2 (hu) | 2008-06-19 | 2018-12-28 | Takeda Pharmaceuticals Co | Heterociklusos vegyület és ennek alkalmazása |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
EP2733145A1 (en) | 2009-10-14 | 2014-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
PE20121699A1 (es) | 2010-02-26 | 2012-12-22 | Xenon Pharmaceuticals Inc | Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica |
WO2014146111A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Analgesic compounds and methods of use |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
CN112940075B (zh) * | 2021-01-07 | 2023-03-31 | 渤海大学 | 一种乙酰胆碱酯酶抑制肽及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654287A (en) * | 1970-08-26 | 1972-04-04 | Mead Johnson & Co | Spiroindanylpiperidines |
US3962259A (en) * | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
GB1435054A (en) * | 1974-02-04 | 1976-05-12 | Ici Ltd | Dihydroanthracene derivatives |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
WO1995028389A1 (fr) * | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
CN1258294A (zh) * | 1997-05-30 | 2000-06-28 | 万有制药株式会社 | 2-氧代咪唑衍生物 |
US6166209A (en) * | 1997-12-11 | 2000-12-26 | Hoffmann-La Roche Inc. | Piperidine derivatives |
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
AU2001288110A1 (en) * | 2000-09-27 | 2002-04-08 | Takeda Chemical Industries Ltd. | Spiro compounds |
-
2002
- 2002-03-06 US US10/092,040 patent/US20030078278A1/en not_active Abandoned
- 2002-05-22 US US10/153,310 patent/US20030078279A1/en not_active Abandoned
- 2002-06-17 BR BR0211305-8A patent/BR0211305A/pt not_active IP Right Cessation
- 2002-06-17 CA CA002450550A patent/CA2450550A1/en not_active Abandoned
- 2002-06-17 WO PCT/IB2002/002272 patent/WO2003000677A1/en not_active Application Discontinuation
- 2002-06-17 MX MXPA03011956A patent/MXPA03011956A/es unknown
- 2002-06-17 US US10/481,210 patent/US20050038060A1/en not_active Abandoned
- 2002-06-17 JP JP2003507081A patent/JP2005521630A/ja active Pending
- 2002-06-17 EP EP02730637A patent/EP1399432A1/en not_active Withdrawn
- 2002-06-20 AP APAP/P/2002/002562A patent/AP2002002562A0/en unknown
- 2002-06-24 PE PE2002000550A patent/PE20030132A1/es not_active Application Discontinuation
- 2002-06-25 SV SV2002001115A patent/SV2003001115A/es unknown
- 2002-06-25 UY UY27355A patent/UY27355A1/es not_active Application Discontinuation
- 2002-06-26 PA PA20028549101A patent/PA8549101A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA03011956A (es) | 2004-03-26 |
PA8549101A1 (es) | 2003-01-24 |
WO2003000677A1 (en) | 2003-01-03 |
JP2005521630A (ja) | 2005-07-21 |
US20030078278A1 (en) | 2003-04-24 |
BR0211305A (pt) | 2004-07-13 |
CA2450550A1 (en) | 2003-01-03 |
US20030078279A1 (en) | 2003-04-24 |
US20050038060A1 (en) | 2005-02-17 |
AP2002002562A0 (en) | 2002-06-30 |
PE20030132A1 (es) | 2003-02-28 |
UY27355A1 (es) | 2003-02-28 |
EP1399432A1 (en) | 2004-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2003001115A (es) | Compuestos de espiropiperidina como ligandos para el receptor orl-1, ref. pc9989. | |
UY26689A1 (es) | Activadores de glucocinasa que contienen hidantoina | |
PA8576901A1 (es) | Moduladores del receptor de glucocorticoides | |
CO6382118A2 (es) | Nuevas octahidrociclopenta(c)ciprol-4aminas sustituidas como bloqueantes de los canales de calcio | |
SV2009002876A (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1 | |
GT200200220A (es) | Nuevos derivados de pirrolidina | |
SV2006002103A (es) | Compuestos de aril- o heteroarilamida ortosustituidos ref. pc32242a | |
ECSP045392A (es) | Moduladores tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos de la actividad de receptores de quimiocina | |
PA8468401A1 (es) | Compuestos para el tratamiento de la isquemia | |
GT200200120A (es) | Ligandos del receptor de 5-ht y sus usos | |
PE20090888A1 (es) | Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119 | |
AR030893A1 (es) | Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos | |
HN2003000094A (es) | Indazoles subtituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion. | |
HN2008001934A (es) | 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen. | |
GT200400226A (es) | Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos | |
CR11096A (es) | Extrudidos con enmascaramiento del sabor mejorado | |
EA200970705A1 (ru) | Новые фармацевтические композиции | |
UY28538A1 (es) | Derivados de fenil-piperazina como moduladores de receptores muscarínicos | |
AR057937A1 (es) | Proceso quimico | |
GT200300046A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
DK1096936T3 (da) | Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister | |
PA8563601A1 (es) | Acidos-3-(imidazolil)-2- alcoxipropanoicos | |
GT200300183A (es) | Nuevos agonistas ppar-alfa y ppar-gamma | |
AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
ES2196069T3 (es) | Derivados morfinoides condensados con heterociclos. |